Longitudinal Outcomes of Dolutegravir-Based Antiretroviral Therapy in a Large Nigerian Programmatic HIV-1 Cohort, 2017–2019

Authors:

Abstract
In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%–82% among participants with available viral load data and 63%–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
Funding Information
  • Cipher
  • Zukunftskolleg, Universität Konstanz
  • International AIDS Society
  • International Health
  • Wellcome Trust (WT108082AIA)
  • Hong Kong Jockey Club Global Health Institute
  • Hong Kong Special Administrative Region

This publication has 19 references indexed in Scilit: